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Abstract	  
Psoriasis	  is	  a	  multifaceted	  disorder	  known	  to	  primarily	  affect	  keratinocytes,	  blood	  vessels,	  and	  
the	  immune	  system.	  	  The	  CD1	  KC-­‐Tie2	  murine	  model	  manifests	  symptoms	  analogous	  to	  those	  
experienced	  by	  those	  125	  million	  psoriasis	  patients	  worldwide.	  	  In	  order	  to	  investigate	  the	  
underlying	  causes	  a	  topical	  treatment,	  solenopsin,	  was	  applied	  to	  the	  psoriasiform	  model.	  	  After	  
four	  weeks,	  decrease	  in	  epidermal	  thickness	  was	  noted.	  	  Additionally,	  CD4+	  T	  cells,	  CD8+	  T	  cells,	  
and	  CD11c+	  dendritic	  cells	  numbers	  were	  significantly	  reduced.	  	  Measurements	  of	  hallmark	  
mRNA	  transcripts	  further	  demonstrate	  to	  reduction	  of	  T	  cell	  numbers	  and	  their	  downstream	  
products.	  	  The	  data	  collected	  suggest	  control	  of	  the	  T-­‐helper17	  pathway,	  via	  application	  of	  
topical	  solenopsin,	  reinstates	  the	  wild	  type	  phenotype	  for	  the	  KC-­‐Tie2	  model.	  	  	  	  	  	  	  	  
Introduction	  
Psoriasis	  
Psoriasis	  is	  an	  autoimmune	  disorder	  characterized	  by	  chronic	  inflammation	  (3,11).	  	  Approximately	  
1.5%	  of	  the	  United	  States	  population,	  over	  three	  million	  individuals,	  is	  inflicted	  with	  this	  disease.	  	  
The	  precise	  causes	  of	  psoriasis	  have	  yet	  to	  be	  elucidated,	  but	  the	  autoimmune	  disorder	  is	  
understood	  to	  have	  both	  genetic	  and	  environmental	  cues	  (9).	  	  The	  inheritance	  pattern	  is	  
unknown,	  but	  frequency	  of	  inheritance	  within	  familial	  studies	  suggests	  a	  degree	  beyond	  random	  
inheritance.	  	  Patients	  experience	  alleviated	  symptoms	  through	  the	  summer	  months,	  due	  to	  
increased	  sun	  exposure,	  yet	  symptoms	  aggravate	  in	  the	  winter	  (3).	  	  A	  combination	  of	  
pathogenesis	  within	  the	  integumentary,	  immune,	  circulatory,	  and	  nervous	  systems	  produces	  the	  
disease’s	  manifestations	  (9,11).	  	  	  
Figure	  1:	  Extracutaneous	  demarcated,	  erythematous	  plaques	  characteristic	  of	  psoriasis	  (Panel	  A&C).	  	  
Psoriatic	  Arthritis	  affects	  5	  –	  20%	  of	  psoriasis	  patients	  (Panel	  B).(9)	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Keratinocytes,	  the	  major	  cell	  contributing	  to	  skin	  structure,	  replicate	  within	  the	  stratum	  basale	  
of	  the	  epidermis.	  	  These	  cells	  mature	  over	  thirty	  days	  and	  are	  forced	  upward	  by	  the	  newly	  
replicating	  keratinocytes	  below.	  	  The	  maturation	  process	  involves	  producing	  keratin	  fibers	  at	  the	  
stratum	  spinosum,	  loss	  of	  nuclei	  and	  cellular	  death	  at	  the	  stratum	  granulosum,	  and	  sloughing	  off	  
of	  dead	  cells	  at	  the	  stratum	  corneum.	  	  However,	  the	  keratinocytes	  in	  psoriatic	  skin	  undergo	  
hyperproliferation,	  taking	  only	  three	  to	  five	  days	  to	  depart	  the	  stratum	  basale,	  which	  obscures	  
the	  standard	  phases.	  The	  pathogenesis	  results	  in	  parakeratosis,	  which	  is	  the	  retention	  of	  nuclei,	  
and	  acanthosis,	  the	  retention	  of	  stratified,	  squamous	  keratinocytes	  in	  the	  epidermis.	  	  The	  
malformation	  causes	  skin	  thickening	  and	  scaling,	  and	  excess	  cells	  form	  extracutaneous	  
demarcated	  silvery	  plaques	  (Figure	  1).	  	  The	  vasculature	  of	  the	  body	  undergoes	  an	  increased	  
level	  of	  angiogenesis	  and	  capillaries	  at	  the	  skin	  surface	  have	  markedly	  thinner	  endothelium.	  	  The	  
changes	  in	  the	  microvasculature	  generate	  the	  erythematous	  coloration	  of	  the	  plaques	  (9).	  
The	  main	  immune	  cells	  leading	  to	  the	  pathogenesis	  of	  the	  disease	  are	  CD4+,	  CD8+	  T	  cells,	  and	  
dendritic	  cells.	  Tissue	  necrosis	  factor	  alpha	  (TNFα)	  has	  been	  correlated	  as	  a	  main	  cytokine	  in	  the	  
inflammation	  of	  disease,	  and	  Interferon	  gamma	  (IFNγ)	  plays	  a	  similar	  inflammatory	  role	  (9).	  	  
Thelper1	  (Th1)	  cytokines,	  IL-­‐23,	  IL-­‐12,	  and	  INFγ	  are	  elevated,	  while	  Thelper17	  (Th17)	  IL-­‐17	  and	  
IL-­‐22	  exhibit	  similar	  increases	  (9).	  	  Thelper2	  (Th2)	  cytokines	  remain	  stagnant	  in	  comparing	  the	  
healthy	  and	  the	  psoriatic	  model.	  Regulatory	  T	  cells	  (Treg)	  release	  less	  anti-­‐inflammatory	  IL-­‐10,	  
further	  allowing	  the	  hallmark	  inflammatory	  response	  in	  psoriasis	  (3,9).	  
These	  adaptive	  immunity	  signatures	  recruit	  adhesion	  molecules	  on	  the	  surface	  of	  endothelial	  
cells	  and	  keratinocytes,	  leading	  to	  heightened	  numbers	  of	  innate	  immune	  cells	  (neutrophils,	  
dendritic	  cells,	  and	  macrophages)	  to	  the	  dermis	  (3).	  	  Leukocytes	  then	  migrate	  from	  the	  skin’s	  
dermis	  layer	  and	  chronically	  persist	  in	  the	  epidermal	  layer	  (3).	  	  This	  autoimmune	  response	  causes	  
keratinocytes	  to	  release	  increased	  amounts	  of	  antimicrobial	  peptides	  s100a8	  and	  s100a9,	  as	  the	  
body	  believes	  a	  foreign	  substance	  is	  in	  the	  body	  (3,9).	  	  
KC-­‐Tie2	  murine	  model	  
The	  KC-­‐Tie2	  model	  is	  a	  CD1	  murine	  system	  exhibiting	  the	  phenotype	  characteristic	  of	  human	  
psoriasis	  (Figure	  2).	  	  Tie2	  is	  an	  angiopoietin	  (a	  vascular	  growth	  factor)	  receptor,	  and	  it	  is	  localized	  
within	  the	  keratinocytes,	  of	  the	  namesake	  KC,	  within	  epidermis	  (11).	  	  Overexpression	  of	  this	  
protein	  only	  in	  keratinocytes,	  not	  endothelial	  cells,	  leads	  to	  the	  classical	  manifestations	  of	  
psoriasis	  (11).	  	  Extensive	  acanthosis,	  infiltrating	  and	  increasing	  CD8+	  and	  CD4+	  T	  cells,	  dendritic	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cells,	  and	  macrophages	  is	  evident	  in	  the	  model	  (11).	  	  Furthermore,	  the	  psoriatic	  cytokine	  
signature	  of	  human	  psoriasis	  is	  represented	  by	  increases	  in	  proinflammatory	  TNFα,	  IFNγ,	  
interleukins	  1α,	  6,	  12,	  22,	  23,	  and	  17,	  and	  host	  defense	  molecules	  β-­‐defensin,	  s100A8,	  and	  
s100A9	  amplification	  (11).	  	  The	  murine	  model	  also	  shows	  phenotype	  relief	  when	  common	  
psoriatic	  treatment	  drugs	  are	  applied.	  	  The	  model	  is	  suitable	  for	  studying	  he	  mechanisms	  of	  
psoriasis	  and	  potential	  treatments	  as	  it	  meets	  clinical,	  histological,	  immunophenotypic,	  
biochemical,	  and	  pharmacological	  criteria	  for	  an	  animal	  model	  of	  psoriasis	  (11).	  	  
Current	  Treatments	  
Treatments	  generally	  vary	  depending	  on	  the	  severity	  of	  the	  disease.	  	  Less	  severe	  cases	  are	  
treated	  with	  topical	  medicines.	  	  Vitamin	  D3	  analogs	  slow	  the	  growth	  of	  skin	  cells,	  topical	  retinoid	  
tazarotene	  normalizes	  the	  DNA	  movement	  of	  keratinocytes,	  and	  topical	  corticosteroids	  are	  
commonly	  prescribed	  for	  moderate	  cases	  (3).	  	  This	  drug	  combination	  affects	  both	  the	  
keratinocyte	  and	  immune	  cells	  malfunctioning,	  while	  the	  corticosteroids	  relieve	  the	  drug’s	  
common	  side	  effects:	  inflammation.	  	  More	  severe	  cases	  require	  the	  use	  of	  phototherapy,	  also	  
known	  as	  artificial	  tanning,	  and	  systematic	  drugs	  (3).	  	  As	  these	  drugs	  are	  toxic	  to	  the	  human	  
body,	  long-­‐term	  use	  is	  not	  recommended.	  	  While	  psoriasis	  manifests	  within	  the	  skin,	  psoriatic	  
patients	  have	  morbidities	  impairing	  normal	  life	  comparable	  to	  diabetes,	  cancer,	  and	  rheumatoid	  
arthritis	  (9).	  	  Physicians	  are	  trained	  to	  address	  this	  psychosocial	  element	  by	  appropriately	  
touching	  their	  skin	  to	  comfort	  the	  patient	  and	  show	  them	  that	  the	  disease	  is	  neither	  contagious	  
nor	  repulsive.	  	  There	  is	  currently	  no	  cure	  for	  psoriasis	  (4).	  	  The	  aspects	  of	  the	  disease	  that	  are	  
currently	  the	  common	  targets	  for	  developing	  drugs	  are	  decreasing	  the	  number	  of	  pathogenic	  T	  
cells,	  blocking	  T	  cell	  migration	  into	  the	  higher	  cutaneous	  layers,	  and	  inhibiting	  cytokines	  via	  
Figure	  2:	  Phenotype	  comparison	  of	  psoriasis	  
model,	  KC-­‐Tie2	  and	  Control	  mouse	  (11).	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blocking	  substances	  (3,9).	  	  This	  paper	  pertains	  to	  the	  application	  and	  investigation	  of	  a	  topical	  
psoriasis	  treatment	  named	  solenopsin.	  	  	  
Solenopsin	  	  
Solenopsin	  is	  naturally	  found	  in	  the	  venom	  of	  fire	  ant	  Solenopsis	  invicta.	  	  Solenopsin,	  C17H35N,	  is	  
an	  alkaloid	  molecule,	  containing	  a	  heterocyclic	  nitrogen	  ring	  structure	  (Figure	  3).	  It	  acts	  in	  the	  
regulatory	  pathway	  of	  angiogenesis.	  	  The	  compound	  does	  not	  cause	  the	  swelling	  characteristic	  
to	  fire	  ant	  bites,	  but	  rather	  it	  acts	  as	  a	  cardiorespiratory	  depressant.	  	  Application	  can	  cause	  
seizures	  in	  rats,	  and	  may	  be	  the	  cause	  of	  cardiorespiratory	  failure	  in	  human	  models	  that	  have	  
experienced	  excessive	  bodily	  stinging	  (6).	  	  The	  compound	  was	  found	  to	  inhibit	  angiogenesis	  both	  
in	  vivo,	  embryonic	  zebrafish,	  and	  in	  vitro,	  via	  SVR	  angiogenesis	  assay	  (1).	  	  Later	  studies	  showed	  
similarities	  to	  ceramide,	  a	  lipid	  common	  within	  the	  plasma	  membranes	  of	  cells,	  which	  regulates	  
cell	  apoptosis.	  	  Ceramides	  are	  correlated	  to	  a	  decrease	  in	  cellular	  proliferation	  and	  death	  of	  
tumor	  cells	  within	  human	  melanoma	  models	  (7).	  	  Solenopsin’s	  effects	  on	  hyperproliferating	  
tumor	  cells	  demonstrate	  a	  potentially	  interesting	  treatment	  option	  against	  the	  hallmark	  
hyperproliferating	  keratinocytes	  of	  psoriasis.	  	  Solenopsin-­‐12	  [S12]	  (Figure	  4)	  and	  Solenopsin-­‐14	  
[S14]	  (Figure	  5)	  have	  carbon	  chains	  of	  twelve	  and	  fourteen	  carbons	  respectively,	  instead	  of	  the	  
eleven	  carbon	  chain	  in	  Figure	  3.	  The	  ingredients	  within	  the	  cream:	  400	  μl	  ethanol,	  40	  g	  
Lipoderm,	  and	  200	  mg	  S12	  or	  S14.	  	  	  	  	  






Figure	  3:	  Solenopsin	  structure	  (C17H35N)	   Figure	  4:	  Solenopsin	  12	  structure	  (C18H37N)	  
Figure	  5:	  Solenopsin	  14	  structure	  C20H41N	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Materials	  and	  Methods	  
Mouse	  
Experimental	  S12	  and	  S14	  creams	  were	  obtained	  from	  Dr.	  Jack	  Arbiser	  at	  Emory	  University.	  	  
Twenty-­‐six	  adult	  KC-­‐Tie2	  background	  mice	  underwent	  daily	  treatment	  for	  the	  duration	  of	  four	  
weeks.	  	  S12	  mice	  (n=9)	  were	  shaved	  as	  needed	  and	  approximately	  125	  mg	  of	  topical	  S12	  cream	  
was	  applied	  dorsally	  in	  an	  upward	  motion,	  against	  the	  natural	  hair	  grain,	  resulting	  in	  a	  thin	  layer.	  	  
S14	  mice	  (n=9)	  underwent	  the	  same	  type	  of	  treatment	  with	  its	  namesake	  cream.	  	  Control	  mice	  
(n=8)	  were	  only	  shaved	  as	  needed.	  	  Application	  occurred	  daily	  near	  10	  am,	  and	  gloves	  were	  
changed	  in	  between	  groups	  to	  avoid	  cross-­‐contamination.	  	  Mice	  were	  euthanized	  via	  Avertin	  
injection.	  Dorsal	  hair	  was	  shaved	  off	  and	  skin	  was	  treated	  for	  either	  frozen	  or	  paraffin	  
sectioning.	  For	  paraffin	  sectioning,	  skin	  was	  placed	  in	  10%	  buffered	  formalin	  (Surgipath	  Medical	  
Industries,	  Richmond,	  IL),	  overnight	  at	  4	  °C	  prior	  to	  dehydration	  and	  embedding	  (Sakura	  
Finetech,	  Torrance,	  CA).	  For	  frozen	  sectioning,	  skin	  was	  placed	  in	  tissue	  freezing	  medium	  (TFM)	  
and	  flash	  frozen	  in	  liquid	  nitrogen.	  	  
Acanthosis	  
Hematoxylin	  and	  eosin	  (H&E)	  staining	  was	  completed	  on	  paraffin	  sections.	  Images	  were	  
captured	  using	  a	  Leica	  DM	  L82	  microscope	  with	  an	  attached	  Q	  Imaging	  MicroPublisher	  3.3	  Mega	  
Pixel	  camera	  and	  Q-­‐capture	  Pro	  software.	  Epidermal	  thickness	  was	  quantified	  using	  Image	  Pro	  
Plus	  software	  (MediaCybernetics,	  Bethesda,	  MD).	  For	  each	  mouse,	  six	  to	  ten	  measurements	  
were	  taken	  from	  at	  least	  five	  different	  fields	  of	  view	  from	  one	  section.	  	  Epidermal	  thickness	  was	  
measured	  from	  the	  stratum	  basale	  to	  stratum	  granulosum,	  and	  excluded	  the	  stratum	  corneum	  
and	  hair	  follicles.	  	  	  
Immunohistochemistry	  	  
Immunohistochemistry	  against	  CD4	  (CD4+	  T	  cell	  marker),	  CD8	  (CD8+	  T	  cell	  marker),	  CD11c	  
(CD11c+	  dendritic	  cell	  marker),	  and	  F4/80	  (F4/80+	  macrophage	  marker)	  was	  performed	  on	  TFM-­‐
embedded	  frozen	  skin	  sectioned,	  using	  specific	  anti-­‐CD4,	  anti-­‐CD8,	  anti-­‐CD11c	  (BD	  Biosciences,	  
San	  Jose,	  CA),	  and	  anti-­‐F4/80	  (eBioscience,	  San	  Diego,	  CA)	  antibodies.	  Antibodies	  were	  detected	  
using	  either	  rabbit	  anti-­‐rat	  IgG	  biotinylated	  (CD4,	  F4/80;	  Vector	  labs,	  Burlingame,	  CA)	  or	  goat	  
anti-­‐hamster	  IgG	  biotinylated	  (CD11c;	  Jackson	  Immunoresearch	  labs,	  West	  Grove,	  PA),	  amplified	  
with	  Avidin/Biotinylated	  Enzyme	  Complex	  (Vector	  labs)	  and	  were	  visualized	  using	  the	  enzyme	  
substrate	  diaminobenzidine	  (Vector	  labs).	  The	  slides	  were	  counterstained	  with	  hematoxylin.	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result	  of	  microarray	  analysis	  performed	  by	  a	  collaborator,	  Dr.	  Arbiser,	  at	  Emory	  University.	  	  	  
Images	  were	  captured	  as	  aforementioned.	  For	  quantification	  of	  CD11c+	  and	  F4/80+	  cells,	  image	  
analyses	  was	  completed	  in	  a	  blinded	  fashion	  using	  an	  automated	  Metamorph	  software	  program	  
(Molecular	  Devices,	  Sunnyvale,	  CA)	  from	  at	  least	  five	  fields	  of	  view	  per	  animal.	  Quantification	  of	  
CD4+	  and	  CD8+	  cells	  were	  hand	  counted	  in	  blinded	  fashion	  from	  at	  least	  five	  fields	  of	  view	  per	  
animal.	  
MECA	  	  
Blood	  vessel	  analyses	  were	  completed	  on	  flash	  frozen	  tissue	  using	  a	  specific	  primary	  antibody	  
targeting	  the	  pan	  mouse	  endothelial	  cell	  antigen	  (MECA;	  Developmental	  Studies	  Hybridoma	  
Bank,	  Iowa	  City,	  IA),	  followed	  by	  detection	  using	  a	  rabbit	  anti-­‐rat	  IgG	  biotinylated	  antibody,	  
amplified	  with	  Avidin/Biotinylated	  Enzyme	  Complex,	  and	  visualized	  using	  the	  enzyme	  substrate	  
diaminobenzidine.	  The	  slides	  were	  counterstained	  with	  hematoxylin.	  Photographs	  were	  taken	  
and	  image	  analyses	  completed	  in	  a	  blinded	  fashion	  using	  an	  automated	  Metamorph	  software	  
program	  (Molecular	  Devices).	  Background	  staining	  was	  minimal	  therefore	  color	  thresholds	  were	  
not	  altered	  between	  samples.	  Four	  fields	  of	  view	  from	  about	  six	  individual	  sections	  were	  
analyzed	  per	  animal.	  	  
mRNA	  
mRNA	  transcript	  analyses	  were	  completed	  on	  flash	  frozen	  tissue.	  	  Tissue	  was	  homogenized	  
using	  Mikro	  Dismembrator	  S	  (Sartorius)	  and	  mRNA	  was	  isolated	  via	  standard	  manufacturer	  
protocol	  using	  a	  Rneasy	  Mini	  Kit	  (Qiagen)	  and	  underwent	  reverse	  transcription	  to	  form	  stable	  
cDNA.	  	  Primers	  and	  cDNA	  were	  measured	  with	  qPCR	  in	  triplicate	  using	  Stepone	  realtime	  PCR	  
(Applied	  Biosystem,	  Foster	  City,	  CA).	  	  The	  thermocycler	  used	  the	  following	  protocol:	  Step	  1	  50	  
°C;	  2min,	  Step	  2	  95	  °C;	  10min,	  Step	  3	  95	  °C;	  15sec,	  Step	  4	  60	  °C;	  1min,	  Step	  5	  go	  to	  Step	  3	  for	  
40cycles.	  	  Transcripts	  and	  respective	  primers	  tested:	  TNFα;	  Mm01336295_m1,	  IFNγ;	  
Mm00802029_m1,	  IL-­‐22;	  Mm01226722_g1,	  IL-­‐22RA2;	  Mm01192969_m1,	  IL-­‐1F5;	  
Mm01333586_m1,	  IL-­‐1F6;	  Mm00457645_m1,	  IL-­‐1F8;	  Mm01337546_g1,	  IL-­‐1F9;	  
Mm00463327_m1,	  IL-­‐34;	  Mm01243248_m1,	  IL17a;	  Mm00439618_m1,	  IL-­‐17c;	  
Mm00521397_m1,	  IL-­‐17f;	  Mm00521423_m1,	  KLK5;	  Mm01203811_m1,	  s100a8;	  
Mm00496696_g1,	  s100a9;	  Mm00656925_m1,	  defb3;	  Mm04214158,	  IL12B/P40;	  
Mm01288989_m1,	  and	  IL23a;	  Mm00518984_m1.	  	  These	  transcripts	  were	  quantified	  and	  
compared	  to	  those	  of	  GAPDH.	  	  Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  is	  constitutively	  
expressed.	  	  Markers	  were	  selected	  due	  to	  prevalence	  in	  psoriasis,	  and	  others	  were	  chosen	  as	  a	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Statistical	  analysis	  	  
All	  data	  sets	  are	  represented	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  At	  least	  seven	  
animals	  for	  each	  group	  were	  used	  for	  statistical	  analyses.	  Between	  group	  comparisons	  were	  
analyzed	  using	  an	  unpaired,	  two-­‐tailed	  Student’s	  t-­‐test	  and	  one-­‐tailed	  Student’s	  t-­‐test.	  	  Figures	  
with	  one	  asterisk	  (*)	  denote	  significance	  with	  a	  one-­‐tailed	  t-­‐test,	  while	  two	  asterisks	  (**)	  signify	  
statistical	  significance	  with	  a	  two-­‐tailed	  t-­‐test.	  	  Statistical	  significance	  was	  defined	  as	  P	  <	  0.05.	  	  
Results	  and	  Discussion	  
Solenopsin	  reduces	  psoriasiform	  skin	  phenotype	  in	  KC-­‐Tie2	  mice	  	  	  
KC-­‐Tie2	  mice	  treated	  with	  the	  solenopsin	  analogs	  S12	  and	  S14	  show	  significant	  reduction	  in	  
disease	  severity.	  	  Both	  creams	  resulted	  in	  significant	  decreases	  in	  epidermal	  thickness	  (Figure	  
6,7)	  and	  dermis	  infiltrating	  CD4+	  T	  cell	  numbers	  (Figure	  8,9).	  The	  S14	  treated	  mice	  had	  
significantly	  reduced	  CD8+	  T	  cells	  (Figure	  10,11)	  and	  CD11c+	  dendritic	  cells	  (Figure	  12,13).	  The	  
Figure	  6:	  Representative	  H&E	  staining	  for	  KC-­‐Tie2	  control	  group	  (Panel	  A).	  S12	  (Panel	  B),	  and	  S14	  (Panel	  C)	  
representative	  pictures	  displaying	  decreased	  acanthosis.	  	  
A	   B	   C	  
100μm	  100μm	  100μm	  
Figure	  7:	  Acanthosis	  measurements	  show	  a	  marked	  
decrease	  in	  S12	  and	  S14	  versus	  control.	  	  The	  black	  
line	  represents	  standard	  CD1	  background	  mouse	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corresponding	  counts	  in	  the	  S12	  group	  showed	  significantly	  decreased	  CD11c+	  and	  a	  downward	  
trend	  of	  CD8+.	  	  Decrease	  in	  dermal	  infiltrating	  F4/80	  macrophages	  was	  not	  observed	  (Figure	  14).	  
Dermal	  angiogenesis	  via	  MECA	  endothelial	  cell	  staining	  did	  not	  display	  increase	  of	  blood	  vessel	  
area	  (data	  not	  shown),	  length	  (data	  not	  shown),	  or	  number	  (Figure	  15).	  	   	  
Histological	  H&E	  staining	  examination	  revealed	  the	  S12	  experimental	  group	  epidermis	  thickness	  
(acanthosis)	  experienced	  significant	  decrease	  (n=9,	  35.509+/-­‐1.91	  µm,	  P<0.001),	  reduced	  by	  
19.168	  µm	  when	  compared	  to	  the	  KC-­‐Tie2	  control	  group.	  	  Similarly,	  the	  S14	  experimental	  group	  
epidermis	  thickness	  experienced	  significant	  decrease	  (n=9,	  39.275+/-­‐1.318	  µm,	  P<0.001),	  
reduced	  by	  15.402	  µm	  when	  compared	  to	  the	  KC-­‐Tie2	  control	  littermates.	  	  Psoriasis	  
characteristic	  acanthosis	  was	  reduced	  in	  the	  S12	  and	  S14	  KC-­‐Tie2	  mice,	  but	  not	  to	  the	  extent	  of	  
simply	  CD1	  mice.	  	  S12	  CD4+	  T	  cells	  were	  significantly	  reduced	  nearly	  2-­‐fold	  (19.564+/-­‐1.15	  cells,	  
Figure	  8:	  	  CD4+	  Staining	  of	  KC-­‐Tie2	  control	  (Panel	  A),	  S12	  (Panel	  B),	  and	  S14	  (Panel	  C)	  demonstrate	  
reduced	  numbers	  of	  cells	  after	  treatment	  
A	   B	   C	  
100μm	  100μm	  100μm	  
Figure	  9:	  CD4+	  T	  cells	  are	  significantly	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P=0.001).	  S14	  CD4+	  T	  cells	  were	  significantly	  reduced	  approximately	  2.75-­‐fold	  (13.500+/-­‐0.795	  
cells,	  P<0.001).	  	  CD8+	  T	  cells	  were	  significantly	  reduced	  nearly	  2-­‐fold	  in	  the	  S14	  treatment	  
(3.957+/-­‐0.552,	  P=0.012),	  while	  S12	  mice	  CD8+	  T	  cells	  demonstrated	  a	  slightly	  negative	  trend	  
versus	  control	  mice	  (6.343+/-­‐1.46,	  P=0.56).	  	  S14	  CD11c+	  dendritic	  cells	  were	  significantly	  
reduced	  over	  1-­‐fold	  (45.20+/-­‐2.956,	  P=0.044).	  	  S12	  CD11c+	  dendritic	  cells	  were	  significantly	  
reduced	  versus	  control	  mice	  (46.415+/-­‐1.458	  cells,	  P=0.56).	  	  S14	  MECA	  stained	  blood	  vessel	  
numbers	  exhibited	  minimal	  differences	  from	  control	  (31.443+/-­‐1.73,	  P=0.80),	  length	  (15.519+/-­‐
0.654,	  P=0.18)	  (data	  not	  shown),	  and	  area	  (65.654+/-­‐5.76,	  P=0.11)	  (data	  not	  shown).	  	  S12	  blood	  
vessel	  MECA	  staining	  exhibited	  similar	  trends	  as	  both	  S14	  and	  control	  groups,	  with	  blood	  vessel	  
enumeration	  (32.151+/-­‐2.216,	  P=0.90),	  length	  (16.729+/-­‐1.25,	  P=0.836)	  (data	  not	  shown),	  and	  
area	  (79.159+/-­‐11.32,	  P=0.92)	  (data	  not	  shown).	  	  F4/80	  macrophages	  were	  not	  reduced	  in	  either	  
experimental	  group.	  	  S14	  macrophages	  cell	  numbers	  (113.433+/-­‐9.57,	  P=0.87)	  and	  S12	  
(123.518+/-­‐4.35,	  P=0.29).	  	  
Treatment	  with	  S14	  significant	  decreases	  versus	  control	  models	  in	  DEFB3	  (0.018+/-­‐0.004,	  
P=0.046	  1-­‐tailed	  t-­‐test)	  (Figure	  16)	  and	  IL-­‐22	  (0.00002+/-­‐0.000003,	  P=0.0317	  2-­‐tailed	  t-­‐test)	  	  
Figure	  10:	  CD8+	  Stain	  displays	  reduction	  in	  the	  S14	  treated	  mice.	  Control	  Panel	  A,	  S12	  Panel	  B,	  S14	  Panel	  C.	  
C	  B	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Figure	  11:	  CD8+	  cells	  reduced	  in	  S14.	  










Figure	  12:	  CD11c	  Stain	  shows	  reduction	  in	  both	  S12	  and	  S14	  groups.	  	  Control	  Panel	  A,	  S12	  Panel	  B,	  S14	  Panel	  C	  
A	   B	   C	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Figure	  13:	  CD11c+	  cells	  are	  significantly	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Figure	  14:	  F480+	  macrophages	  did	  not	  vary	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Figure	  15:	  MECA+	  cells	  staining	  blood	  vessels	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(Figure	  17).	  	  Juxtaposed,	  IFNy	  (0.0001+/-­‐0.00002,	  P=0.073	  1-­‐tailed	  t-­‐test)	  (data	  not	  shown)	  and	  
IL-­‐17c	  (0.002+/-­‐0.0005,	  P=0.037	  1-­‐tailed	  t-­‐test)	  (data	  not	  shown)	  both	  increased	  after	  S14	  
treatment.	  The	  S12	  treatment	  group	  presented	  near	  significant	  decreases	  in	  IL-­‐17F	  (0.0003+/-­‐
0.00008,	  P=0.069	  1-­‐tailed	  t-­‐test)	  (Figure	  18),	  significant	  DEFB3	  (0.021+/-­‐0.004,	  P=0.0463	  1-­‐tailed	  
t-­‐test),	  and	  significant	  IL-­‐22	  (0.00007+/-­‐0.00002,	  P=0.061	  2-­‐tailed	  t-­‐test).	  The	  messenger	  RNA	  
transcripts	  did	  not	  significantly	  fluctuate	  substantially	  amongst	  KLK5,	  IL-­‐34,	  IL1F5,	  IL1F6,	  IL1F8,	  
IL1F9,	  TNFa,	  s100a8,	  s100a9,	  IL-­‐17a,	  IL-­‐12b/p40,	  IL22RA2,	  and	  IL-­‐23a	  (data	  not	  shown).	  	  
The	  cream’s	  molecular	  signature	  was	  analyzed	  via	  enumeration	  of	  immune	  cells,	  typical	  
cytokines,	  chemokines,	  and	  antimicrobial	  peptides	  typically	  detected	  in	  psoriasis	  patients	  (11).	  	  
Daily	  treatment	  with	  solenopsin	  over	  four	  weeks	  upon	  KC-­‐Tie2	  background	  mice,	  mainly	  affects	  
T	  cells,	  both	  CD4+	  (classification	  includes	  Th1,	  Th2,	  and	  Th17	  cells)	  CD8+,	  and	  CD11c+	  dendritic	  
cells.	  	  These	  results	  suggest	  the	  possibility	  of	  regulation	  within	  the	  bridging	  of	  the	  innate	  to	  
adaptive	  immune	  response.	  	  Reducing	  the	  quantity	  of	  dendritic	  cells	  lowers	  to	  amount	  of	  
antigen	  presenting	  cells,	  thus	  less	  self-­‐antigens	  can	  be	  presented	  to	  T	  cells,	  and	  less	  proliferation	  
of	  activated	  T	  cells	  would	  occur.	  	  So,	  less	  T	  cells	  infiltrate	  the	  dermis	  and	  epidermis.	  	  This	  
suppression	  would	  cause	  a	  decrease	  in	  leukocyte	  recruiting	  chemokines,	  and	  help	  explain	  the	  
lowered	  numbers	  of	  dendritic	  cells	  in	  the	  skin.	  	  However,	  this	  is	  only	  one	  possible	  location	  of	  
regulation,	  and	  further	  study	  need	  be	  performed	  to	  isolate	  the	  mechanism	  of	  solenopsin.	  	  	  	  
By	  targeting	  the	  keratinocytes	  directly	  with	  topical	  solenopsin,	  it	  is	  possible	  that	  the	  cream	  is	  























Figure	  16:	  S14	  mice	  had	  significantly	  reduced	  
Defb3.	  
lowering	  the	  amount	  of	  antimicrobial	  peptides,	  such	  as	  β	  -­‐defensin	  and	  s100a9.	  	  This	  reduction	  
may	  lead	  to	  the	  decreased	  autoimmune	  response,	  by	  sending	  negative	  feedback	  signals	  to	  the	  
immune	  system.	  	  The	  lower	  antimicrobial	  peptides	  cause	  the	  leukocytes	  to	  stop	  inflammatory	  
signals,	  as	  the	  “infection”	  of	  the	  autoimmune	  disease	  is	  thought	  to	  be	  cleared.	  	  
Furthermore,	  psoriasis	  is	  known	  to	  affect	  the	  T	  helper	  cellular	  pathways,	  specifically	  up-­‐
regulating	  both	  the	  Th1	  and	  Th17	  cascades	  (9).	  	  Data	  suggests	  that	  solenopsin	  may	  affect	  the	  
Th17	  pathway.	  IL-­‐1	  and	  IL-­‐6	  cause	  Th1	  differentiation	  to	  Th17	  and	  IL-­‐23a	  causes	  proliferation	  of	  
Th17	  cells	  	  (2).	  Investigation	  into	  IL-­‐23a	  and	  IL-­‐1	  derivatives	  in	  the	  experimental	  groups	  displayed	  
Figure	  17:	  IL-­‐22	  mRNA	  transcripts	  are	  











































Figure	  18:	  IL-­‐17f	  transcripts	  were	  significantly	  
decreased	  in	  S12	  mice	  
a	  level	  constant	  with	  that	  of	  the	  control	  cytokines	  (IL-­‐6	  was	  not	  studied).	  	  However,	  further	  
downstream	  investigation	  displays	  regulation	  in	  IL-­‐17	  and	  IL-­‐22.	  	  	  
Previous	  research	  as	  been	  performed	  on	  a	  Janus	  Kinase	  (JAK)	  inhibitor	  called	  tofacitinib	  (10).	  	  JAKs	  
play	  a	  role	  in	  signal	  transduction	  of	  inflammatory	  diseases.	  	  It	  was	  determined	  that	  this	  molecule	  
is	  able	  to	  reduce	  psoriasis	  when	  applied	  as	  a	  cream	  (10).	  	  It	  functions	  by	  blocking	  IL-­‐23,	  and	  thus	  
the	  Th17	  pathway	  of	  inflammation.	  	  The	  topical	  significantly	  reduced	  human	  psoriasis	  using	  the	  
Target	  Plaque	  Severity	  Score	  (10).	  	  However,	  this	  topical	  may	  differ	  from	  solenopsin	  as	  it	  targets	  
the	  immune	  system	  first.	  It	  is	  hypothesized	  that	  solenopsin	  targets	  the	  keratinocytes	  expression	  
of	  proinflammatory	  molecules,	  and	  then	  causes	  downstream	  effects	  through	  the	  immune	  
system.	  	  
In	  the	  solenopsin	  trials,	  three	  members	  of	  the	  IL-­‐17	  family,	  released	  from	  Th17	  cells,	  were	  
investigated:	  IL-­‐17a/c/f.	  	  In	  the	  S12	  model,	  IL-­‐17a	  trended	  downward	  versus	  control,	  IL-­‐17c	  
remained	  near	  control	  levels,	  and	  IL-­‐17f	  was	  significantly	  reduced.	  	  In	  S14	  mice,	  IL-­‐17a	  remained	  
near	  control	  concentration,	  yet	  IL-­‐17c	  was	  found	  at	  higher	  levels	  than	  control	  mice,	  and	  IL-­‐17f	  
remained	  at	  control	  levels.	  	  IL-­‐22	  has	  been	  considered	  the	  key	  cytokine	  regulating	  the	  
proliferation	  in	  psoriasis	  (2),	  and	  mRNA	  analysis	  revealed	  a	  significant	  reduction	  of	  the	  S14	  litter’s	  
transcription	  of	  IL-­‐22,	  while	  the	  S12	  litter	  displayed	  the	  same	  negative	  trend.	  	  TNFα,	  another	  
Th17	  proinflammatory	  cytokine,	  had	  relatively	  stable	  transcription	  in	  all	  groups.	  	  Further	  analysis	  
showed	  trends	  of	  IL-­‐22	  downstream	  reduction	  in	  antimicrobial	  s100a9	  and	  β	  -­‐defensin.	  	  IL-­‐1f8,	  
also	  known	  as	  IL-­‐36b,	  expression	  is	  induced	  via	  IL-­‐22	  (3),	  explaining	  its	  downward	  trend	  in	  both	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experimental	  groups.	  	  Previous	  studies	  have	  shown	  that	  IL-­‐22	  and	  IL-­‐17a/f	  cooperatively	  induce	  
the	  release	  of	  antimicrobial	  peptides,	  explaining	  why	  there	  was	  reduction	  in	  s100a9	  as	  well	  as	  β-­‐
defensin	  in	  solenopsin	  treated	  groups	  (8).	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